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CASE PRESENTATION
The patient is a 48-year-old female who was referred for
a renal transplant evaluation in 2006. She was first
diagnosed with kidney disease in her teens after
presenting with fatigue and general malaise. On referral to
a local nephrologist approximately 30 years ago, an
imaging study was performed demonstrating renal cysts
and the patient was diagnosed to have medullary cystic
kidney disease (MCKD). At the age of 19, the patient was
diagnosed with type 1 diabetes and insulin therapy was
started. Over the next several years, her kidney function
declined slowly (Figure 1).
On presentation for her transplant evaluation, her
major symptom was fatigue, which had not changed
substantially in 30 years. She also had occasional back
pain, which was attributed to bleeding within renal cysts.
The patient had no history of gout or genitourinary tract
anomalies.
There was no history of kidney disease, gout, or
diabetes in first-degree relatives. She has two healthy
brothers and healthy parents and has no children. There is
a paternal family history of diabetes in second-degree
relatives. Her first menses was at age 12 and were regular
until 3 months before her appointment. The patient has
had no pregnancies or miscarriages.
Physical examination revealed a temperature of
36.9 1C, pulse 101, and blood pressure of 128/92 mm Hg.
There was no evidence of dysmorphic features,
pre-auricular pits, or tophi. Her oropharynx was without
lesions and her palatal arch and dentition were normal.
Fundoscopic examination was significant for evidence
of copper wiring with early AV nicking, scattered
microaneurysms without hemorrhage, and sharp disk
margins. Her neck examination showed no goiter or
lymphadenopathy. Cardiovascular examination was
normal and her lung fields were clear to auscultation.
Examination of the abdomen was unrevealing with no
hepatosplenomegaly. There were no flank masses or
tenderness noted.
Laboratory studies at the time of transplant evaluation
showed a creatinine of 2.8 mg/100 ml with an estimated
glomerular filtration rate of 19.9 ml/min/1.73 m2. Urinalysis
was significant for 3þ glucose and 1þ protein and urine
protein/creatinine ratio of 0.6 (Table 1). Her uric acid was
7 mg/100 ml and her C-peptide was 2.5 ng/ml with a
simultaneous blood sugar of 341 mg/ml. Anti-islet cell and
anti-glutamic acid decarboxylase antibodies were both
negative. An MRI showed multiple cysts of varying sizes
throughout both kidneys, some with signal characteristics
consistent with hemorrhage (Figure 2a and b). The body
and tail of the pancreas were severely atrophic
(Figure 2c and d).
CLINICAL DIAGNOSIS
The differential diagnoses that we considered in this case
of cystic renal disease were autosomal dominant polycystic
kidney disease, medullary cystic kidney disease, acquired
cystic kidney disease in a patient with sporadic CKD of
unknown cause, or another genetic renal disease associated
with cysts (Table 2). Although autosomal dominant poly-
cystic kidney disease was a possibility, the kidneys were not
significantly enlarged and there was no evidence of cysts in
the liver or pancreas. The varying sizes and widespread
presence of renal cysts, some with hemorrhage, were atypical
for MCKD. Cysts in patients with MCKD, if present, are
few, small, and confined to the corticomedullary junction.
Acquired cystic kidney disease appeared unlikely, as the
patient was told 25 years ago, when her creatinine was
1.8 mg/100 ml, that the kidney contained cysts. Other less
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common inherited forms of cystic renal disease include
autosomal recessive polycystic kidney disease, juvenile
nephronophthisis, branchiootorenal dysplasia, orofacial
digital syndrome, and renal cysts and diabetes (RCAD).
Autosomal recessive polycystic kidney disease usually pre-
sents in childhood with early-onset renal failure with
enlarged kidneys without visible cysts, although a recent
article suggests that in a significant number of patients who
survive to adulthood, the kidneys do not appear to be
enlarged relative to body size.1 Juvenile nephronophthisis is
associated with small kidneys with occasional cysts in the
corticomedullary junction. Branchiootorenal dysplasia is
associated with deafness, external otic anomalies, and pre-
auricular pits, whereas orofacial digital syndrome is asso-
ciated with facial clefting and polydactyly, features that were
absent in this case. Although her diabetes was diagnosed in
her teens and she was insulin dependent from the start,
further testing at the time of transplant evaluation demon-
strated endogenous insulin secretion and the absence of
serological markers of autoimmune diabetes, thus making
the diagnosis of type 1 diabetes less likely. The combination
of cystic kidney disease with early-onset diabetes and
pancreatic atrophy best fit the genetic disease called RCAD,
also referred to as maturity-onset diabetes of the young
(MODY) type 5.
GENETIC TESTING
To confirm the diagnosis of RCAD, genetic testing from
peripheral blood leukocytes was carried out by PCR
and direct sequencing of exons 1–9 of the gene-encoding
hepatocyte nuclear factor 1b (HNF-1b). This showed a
novel missense mutation within exon 3 at nucleotide 728
(c.728A4C) in the open reading frame of HNF-1b leading to
the substitution of proline, a nonpolar amino acid for
glutamine, an uncharged polar amino acid at codon 243
(Q243P). This missense mutation has not been found in
sequencing over 200 normal chromosomes in European
white subjects (Hattersley, A.T., unpublished data). This
glutamine residue, within the DNA-binding domain of
HNF-1b, is conserved across species and confirmed the
diagnosis of RCAD (Figure 3).
DISCUSSION
Maturity-onset diabetes of the young was first described in
the 1970s and accounts for 1–2% of cases of diabetes mellitus.
The diagnostic criteria for the disease include a family history
of diabetes transmitted in an autosomal dominant pattern
and early onset of diabetes, typically before the age of 25.2
Since its original description, several different genes have
been identified as causing MODY, which are classified into six
subtypes: MODY1 through MODY6. Of these, MODY5 or
RCAD caused by heterozygous mutations in HNF1B is
associated almost universally with developmental renal
abnormalities.3 HNF-1b or transcription factor 2 is a
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Figure 1 | Serum creatinine and estimated glomerular
filtration rate over time.
Table 1 | Labs on presentation with recent LFTs and HgA1c
Sodium 139 meq/l
Potassium 4.0 meq/l
Chloride 103 meq/l
CO2 21 meq/l
BUN 42 mg/100 ml
Creatinine 2.8 mg/100 ml
Uric acid 7.0 mg/100 ml
Urinalysis pH 5.5, SG 1.010, 3+ glucose,
1+ protein
Urine micro 1 WBC/hpf
Urine creatinine 71.6 mg/100 ml
Total protein 44 mg/100 ml
Islet cell Ab, IgG o1:4
Glut acid decarboxylase Ab Negative
ALT 17 U/l
AST 16 U/l
Bilirubin total 0.2 mg/100 ml
Alkaline phosphatase 122 U/100 ml
Gamma glutamyltranspeptidase 46 U/100 ml
HgA1c 10.6%
C-peptide serum 2.5 ng/ml
Glucose 341 mg/100 ml
a b
c d
Figure 2 | MR images of the kidney and pancreas. (a) Coronal
T2 image showing multiple renal cysts bilaterally and atrophy of
the right kidney. (b) Coronal fat-suppressed T1 image shows two
left renal cysts with high signal (arrows) characteristic of subacute
hemorrhage. (c and d) Contrast-enhanced axial fat-suppressed T1
images demonstrate (c) normal pancreatic head (open arrow),
uncinate process (arrowhead), and distal common bile duct
(filled arrow). However, there is (d) absence of pancreatic
parenchyma in the expected locations of the body and tail
(asterisk) anterior to the splenic vein (arrow).
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homeodomain-containing transcription factor that functions
as a homodimer or as a heterodimer with the closely related
HNF-1a.4
RCAD (OMIM no. 137920)
‘Renal cysts and diabetes’ is a newly identified disease
that describes the principal phenotypic presentation of
individuals with a HNF1B mutation. The renal abnormalities
first described were those of multiple simple cysts, but a
variety of other developmental renal abnormalities including
multicystic renal dysplasia, hypoplasia, unilateral renal
agenesis, hypoplastic glomerulocystic kidney disease, oligo-
meganephronia, horseshoe kidney and atypical familial
juvenile hyperuricemic nephropathy are now known to be
Table 2 | Cystic kidney diseases
Disease (inheritance) Protein Gene, locus Clinical features
Autosomal dominant polycystic
kidney disease (AD)
Polycystin 1
Polycystin 2
PKD1, 16p13
PKD2, 4q21
Enlarged kidneys with multiple cysts. Hepatic cysts and intracranial
aneurysm in some. Episodic flank pain, hematuria, hypertension.
Age-dependent penetrance
Autosomal recessive polycystic
kidney disease (AR)
Fibrocystin or
polyductin
PKHD1, 6p Enlarged kidneys with small uniform cysts. Also associated hepatic fibrosis
with portal hypertension. Most present in infancy, and ESRD occurs within a
year. Few present late
Medullary cystic kidney
disease (AD)
Not known
Uromodulin
MCKD1, 1q21
UMOD, 16p12
Small kidneys with few to no cysts in corticomedullary region. Polyuria,
polydypsia, salt wasting. Juvenile gout. ESRD in adulthood
Juvenile nephronophthisis (AR) Nephrocystin NPHP1, 2q13 Small kidneys with few to no cysts in corticomedullary region. Polyuria,
polydypsia, salt wasting, and absence of hypertension. ESRD median:
13 years
Variants:
Incl. Senior–Loken syndrome Inversin INVS, 9q31
Incl. Jouberts syndrome Nephrocystin 3–5 NPHP3–5
Renal cysts and diabetes
MODY5 (AD)
HNF-1b
(transcription
factor 2)
HNF1B, 17cen-q21 Renal developmental defects, for example, cystic renal dysplasia, unilateral
renal agenesis, hypo/dysplastic kidneys. Pancreatic atrophy and insulin
dependence. Genital tract anomalies. Variable expressivity
Tuberous sclerosis (AD) Hamartin
Tuberin
TSC1, 9q34
TSC2, 16p13
Variable cystic enlargement of kidneys. Renal angiomyolipomata in 50%.
Classic skin lesions. Presents with seizures, mental retardation, tumors of
kidney, heart
Von Hippel–Lindau Disease
(AD)
vHL VHL, 3p26 Multifocal renal cell Ca. Multiple renal cysts. CNS hemangioblastoma,
angiomata of retina, liver, lung. Present with visual/CNS abnormalities
Branchiootorenal dysplasia 1
and 2 (AD)
EYA1
SIX5
EYA1, 8q13
SIX5, 19q13
Variable cystic kidneys, renal hypo/dysplasia. deafness, malformed pinnae,
pre-auricular pits, branchial fistulae
Orofacial digital syndrome
type 1 (X-linked dominant)
CXorf5 CXORF5, Xp22 Polycystic kidneys, mental retardation, cleft lip, lobulated tongue, abnormal
fingers and toes. Lethal in hemizygous males. ESRD in females
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Figure 3 | The nucleotide sequence of amplified HNF1B showing a heterozygous missense mutation in the affected patient
compared with that of a normal control. The electropherogram shows the double A/C peak of reduced amplitude at nucleotide position
728 (vertical arrow).
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caused, in some instances, by mutations in HNF1B.3
Hypoplastic glomerulocystic kidney disease is characterized
by small cystic kidneys, malformed renal calyces and pelvis,
and the presence of glomerular cysts on renal biopsy.5
Oligomeganephronia is characterized by renal hypoplasia
with evidence of a substantially reduced number of nephrons,
and on renal biopsy, glomeruli are markedly enlarged.6 Other
nonrenal clinical features of RCAD include pancreatic
atrophy resulting in diabetes and mild exocrine insufficiency,
genitourinary abnormalities such as hypospadias in males
and vaginal aplasia in females, abnormal liver function tests,
and hyperuricemia with early-onset gout.7
How prevalent is RCAD? An analysis of 20 unrelated
white adult patients who had chronic kidney disease with
renal structural abnormalities and early-onset diabetes
without anti-islet cell antibodies identified eight patients
with mutations in HNF1B.8 In another study, HNF1B gene
was analyzed in 160 unrelated European adult subjects with a
variety of renal disease of unknown etiology.3 These included
patients who had been diagnosed with renal cystic disease,
glomerulocystic kidney disease, atypical juvenile hyper-
uricemic nephropathy, renal dysplasia, and unilateral renal
agenesis. Twenty-three (23 of 160) subjects had a coding
region or splice site mutations in HNF1B; moreover, 60% of
mutations were found in patients with renal cysts. Remark-
ably, only 48% of patients with identified mutations had
diabetes at the time of diagnosis and only 26% met the criteria
for MODY. In a recent follow-up study, 15 of the 137 subjects
who had no identifiable mutations by sequencing were found
to have heterozygous whole-gene deletion of HNF1B, leading
to an updated 24% prevalence of HNF1B mutations or
deletions in this series of patients with unexplained renal
disease.9 In a cohort of 80 European children with a median
age of 0.2 years who had renal dysplasia, hypoplasia, unilateral
renal agenesis, and/or renal cysts, and the absence of another
known genetic disease, 25 had an HNF1B mutation.10 More
recently, in another European study, 18 of 56 newborn
infants who on routine scanning were noted to have bilateral
hyperechogenic kidneys in utero were found to have hetero-
zygous HNF1B mutations.11 A summary of the phenotypic
manifestations in case series published thus far on HNF1B
mutations is shown in Table 3.
More than 65 different mutations have now been identi-
fied in 143 families, with the majority of mutations within
the dimerization and DNA binding domains (Figure 4). The
mutations usually result in reduced transcriptional activation
of target genes, although some mutations are dominant
negative and inhibit the function of wild-type HNF-1a or
b.19,20 More recently, it has become evident that a significant
number of mutations that cause RCAD are whole-gene
deletions of a single copy of HNF1B, which may not be
detected by standard amplification and direct sequencing
techniques.9,16 Importantly, many HNF1B mutations are
private, and where parental DNA has been studied, as many
as 50% of mutations occur de novo.10
HNF-1b and renal development
Hepatocyte nuclear factor 1b is known to play a role in
kidney development, with embryonic expression in the
branching ureteric bud.21 Target genes for HNF-1b include
PKHD1, UMOD, and PKD2, genes that when mutated cause
some forms of cystic kidney disease.22 Homozygous or
compound heterozygous mutations of PKHD1 cause auto-
somal recessive polycystic kidney disease, heterozygous
mutations in UMOD cause type 2 MCKD, and heterozygous
mutations in PKD2 cause autosomal dominant polycystic
kidney disease type 2. The protein product of PKHD1,
polyductin/fibrocystin, and that of PKD2, polycystin 2, are
found in the primary cilium, an organelle that extends from
the apex of renal epithelial cells and controls the proliferation
of tubular cells.23 A number of genetic renal cystic diseases
are now shown to be caused by defects in components of
the ciliary proteome.23 Although HNF-1b is not required
for the development of the primary cilium, it is essential for
its function, and hence HNF1B can be considered to be a
ciliopathy gene.
Table 3 | Case series describing mutations in HNF1B
Phenotype
Kidney Diabetes Genital tract Pancreas Other Reference
HGKD + 12
CRD + 13
CRD, URA  + 14
AFJHN, CRD + Hyperuricemia 15
CRD, RHD, OMN + + Elevated LFTs 8
CRD, URA + + + Elevated LFTs 16
CRD, RHD + 17
CRD + 18
CRD, AFJHN, HGKD, HSK, RHD, URA + + Elevated LFTs 3
CRD, RHD a Elevated LFTs 10
CRD, URA, RHD + + + Elevated LFTs, uric acid 9
CRD, BHK +  Elevated LFTs, uric acid 11
AFJHN, atypical familial juvenile hyperuricemic nephropathy; BHK, bilateral hyperechogenic kidneys; CRD, renal cysts including cystic renal dysplasia; HGKD, hypoplastic
glomerulocystic kidney disease; HSK, horseshoe kidney; OMN, oligomeganephronia; RHD, renal hypoplasia/dysplasia; URA, unilateral renal agenesis.
aPediatric cohort.
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Pancreatic abnormalities
Hepatocyte nuclear factor 1b regulates gene expression and
embryonic development in the bile duct, liver, pancreas, lung,
and gut. HNF-1b is involved in early pancreatic development
before exocrine and endocrine differentiation, and the
expression of HNF-1b defines a population of cells that
form primitive pancreatic ducts.24 Pancreatic atrophy and a
gradual decline in basal insulin levels and a decreased
secretory response to glucose and sulfonylureas are compo-
nents of the phenotypic presentation of RCAD/MODY5.3,8
Mice that lack HNF-1b have pancreatic agenesis confirming
the central role of HNF-1b in pancreatic development.25
Genital tract abnormalities
Expression of HNF-1b is seen in the Wolffian duct, the
progenitor of the vas deferens and epididymis, and
the Mullerian duct, which develops into the oviduct, uterus,
and cervix.21 Women with HNF1B mutations have been
found to have bicornuate uteri, single ovaries, hemi-uterus,
and unexplained infertility.3 Males have been shown to have
atresia of the vas deferens, epididymal cysts, and infertility
due to asthenospermia.3
Genetic testing
Genetic testing is now available for patients who are
suspected to have mutations or deletions in HNF1B. These
include patients who have any of a variety of unexplained
developmental renal diseases, particularly those with renal
cysts. The presence of early-onset diabetes with or without
pancreatic atrophy and genital abnormalities is strongly
suggestive of RCAD and can be confirmed by genetic analysis.
CONCLUSIONS
The evidence reviewed here demonstrates the variable
expressivity of HNF1B gene mutations. Clinicians should
be aware of HNF1B mutations as an important and common
cause of a number of developmental renal defects, including
cystic renal disease, and as a cause of early-onset diabetes.
The presence of cystic renal disease and early-onset diabetes
especially when coupled with pancreatic atrophy or geni-
tourinary abnormalities substantially increases the likelihood
that the patient has a mutation in HNF1B. However, the
absence of diabetes or genital tract abnormalities and, as in
our case, a lack of a family history appear to be common in
patients with pathogenic HNF1B mutations. Surprisingly,
despite radiological evidence for substantial pancreatic
atrophy, our patient had no symptoms suggestive of exocrine
pancreatic insufficiency. Proper diagnosis allows for more
accurate prognostication of renal and pancreatic, hepatic,
and genital abnormalities and permits appropriate counsel-
ing in selected cases. Furthermore, in patients referred for
transplantation, identification of the genetic basis of renal
disease allows for more careful selection of organ donors
within the patient’s immediate family.
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R295P
R295C
Q311X
H324S325fsdelCA
P328L329fsdelCCTCT
P334fsinsC
H336D
(2)
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Figure 4 | A schematic of the HNF1B gene structure illustrating the 65 different mutations identified within the coding region
in 143 cases to date. Numbers in parenthesis next to identified mutation indicate the number of probands with the reported mutation. All
other mutations have so far been described in just one proband/kindred. The mutation identified in this report is indicated with an asterisk.
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